Catalyst
Slingshot members are tracking this event:
AbbVie (ABBV) Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ABBV |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 25, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Anti-tau Antibody, Abbv-8e12, Progressive Supranuclear Palsy, Early Alzheimer's Disease
